Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens

Journal of Biomolecular Screening

Volumn 17, Issue 10, 2012, Pages 1279-1292

  Diaz, Elsie ^a   MacHutta, Carl A ^a   Chen, Stephanie ^a   Jiang, Yong ^a   Nixon, Christopher ^a   Hofmann, Glenn ^a   Key, Danielle ^a   Sweitzer, Sharon ^a   Patel, Mehul ^a   Wu, Zining ^a   Creasy, Caretha L ^a   Kruger, Ryan G ^a   Lafrance, Louis ^a   Verma, Sharad K ^a   Pappalardi, Melissa B ^a   Le, Baochau ^a   Van Aller, Glenn S ^a   McCabe, Michael T ^a   Tummino, Peter J ^a   Pope, Andrew J ^a   Thrall, Sara H ^a   Schwartz, Benjamin ^a   Bandt, Martin ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

epigenetics; EZH2; histone methyltransferase; HTS

Indexed keywords

GSK A; PROTEIN INHIBITOR; REAGENT; S ADENOSYLHOMOCYSTEINE; SINEFUNGIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; DRUG IDENTIFICATION; HIGH THROUGHPUT SCREENING; NUCLEOSOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN METHYLATION; VALIDATION PROCESS;

DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDICATORS AND REAGENTS; KINETICS; NUCLEOSOMES; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 2; REPRODUCIBILITY OF RESULTS;

EID: 84869012125     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112453765     Document Type: Article

References (38)

1. Berger S. L., Kouzarides T., Shiekhattar R., Shilatifard A.. An Operational Definition of Epigenetics. Genes Dev. 2009 ; 23: 781-783
2. Margueron R., Reinberg D.. Chromatin Structure and the Inheritance of Epigenetic Information. Nat. Rev. Gen. 2010 ; 11: 285-296
3. Albert M., Helin K.. Histone Methyltransferases in Cancer. Semin. Cell. Dev. Biol. 2010 ; 21: 209-220
4. Martin C., Zhang Y.. The Diverse Functions of Histone Lysine Methylation. Nat. Rev. Mol. Cell. Biol. 2005 ; 6: 838-849
5. Blackledge N. P., Klose R. J.. Histone Lysine Methylation: An Epigenetic Modification?. Epigenomics. 2010 ; 2: 151-161
6. Sneeringer C. J., Scott M. P., Kuntz K. W., Knutson S. K., Pollack R. M., Richon V. M., Copeland R. A.. Coordinated Activities of Wild-Type plus Mutant EZH2 Drive Tumor-Associated Hypermethylation of Lysine 27 on Histone H3 (H3K27) in Human B-cell Lymphomas. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 20980-20985
7. Margueron R., Reinberg D.. The Polycomb Complex PRC2 and Its Mark in Life. Nature. 2011 ; 469: 343-349
8. Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.. EZH2 Requires PHF1 to Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo. Mol. Cell. Biol. 2008 ; 28: 2718-2731
9. Varambally S., Dhanasekaran S. M., Zhou M., Barrette T. R., Kumar-Sinha C., Sanda M. G., Ghosh D., Pienta K. J., Sewalt R. G. A. B., Otte A. P., et al. The Polycomb Group Protein EZH2 Is Involved in Progression of Prostate Cancer. Nature. 2002 ; 419: 624-629
10. Karanikolas B. D. W., Figueiredo M. L., Wu L.. Comprehensive Evaluation of the Role of EZH2 in the Growth, Invasion, and Aggression of a Panel of Prostate Cancer Cell Lines. Prostate. 2010 ; 70: 675-688
11. Raman J. D., Mongan N. P., Tickoo S. K., Boorjian S. A., Scherr D. S., Gudas L. J.. Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder. Clin. Cancer Res. 2005 ; 11: 8570-8576
12. Ougolkov A. V., Bilim V. N., Dilladeau D. D.. Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferases Enhancer of Zeste Homologue 2. Clin. Cancer Res. 2008 ; 14: 6790-6796
13. Crea F., Hurt E. M., Farrar W. L.. Clinical Significance of Polycomb Gene Expression in Brain Tumors. Mol. Cancer. 2010 ; 9: 265
14. Kleer C. G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S. A., Ghosh D., Sewalt R. G. A. B., Otte A. P., Hayes D. F., et al. EZH2 Is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells. Proc. Natl. Acad. Sci. U. S. A. 2003 ; 100: 11606-11611
15. Collett K., Eide G. E., Arnes J., Stefansson I. M., Eide J., Braaten A., Aas T., Otte A., Akslen L. A.. Expression of Enhancer of Zeste Homologue 2 Is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer. Clin. Cancer Res. 2006 ; 12: 1168-1174
16. McCabe M. T., Graves A. P., Ganji G., Diaz E., Halsey W. S., Jiang Y., Smitheman K. N., Ott H. M., Pappalardi M. B., Allen K. E., et al. Mutation of A677 in Histone Methyltransferase EZH2 in Human B-cell Lymphoma Promotes Hypertrimethylation of Histone H3 on Lysine 27 (H3K27). Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 2989-2994
17. Yap D. B., Chu J., Berg T., Schapira M., Cheng S. W., Moradian A., Morin R. D., Mungall A. J., Meissner B., Boyle M., et al. Somatic Mutations at EZH2 Y641 Act Dominantly through a Mechanism of Selectively Altered PRC2 Catalytic Activity, to Increase H3K27 Trimethylation. Blood. 2011 ; 117: 2451-2459
18. Morin R. D., Johnson N. A., Severson T. M., Mungall A. J., An J., Goya R., Paul J. E., Boyle M., Woolcock B. W., Kuchenbauer F., et al. Somatic Mutations Altering EZH2(Tyr641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal-Center Origin. Nat. Genet. 2010 ; 42: 181-187
19. Suh-Lailam B. B., Hevel J. M.. A Fast and Efficient Method for Quantitative Measurement of S-adenosyl-L-methionine-Dependent Methyltransferases Activity with Protein Substrates. Anal. Biochem. 2010 ; 398: 218-224
20. Glickman J. F., Schmid A., Ferrand S.. Scintillation Proximity Assays in High-Throughput Screening. Assay Drug Dev. Tech. 2008 ; 6: 433-455
21. Dhayalan A., Dimitrova E., Rathert P., Jeltsch A.. A Continuous Protein Methyltransferases (G9a) Assay for Enzyme Activity Measurement and Inhibitor Screening. J. Biomol. Screen. 2009 ; 14: 1129-1133
22. Jiang Y., Schneck J., Grimes M., Taylor A., Hou W., Thrall S. H., Sweitzer S.. Methyltransferases Prefer Monomer over Core-Trimmed Nucleosomes as In-Vitro Substrates. Anal. Biochem. 2011 ; 415: 84-86
23. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
24. Coma I., Clark L., Diez E., Harper G., Herranz J., Hofmann G., Lennon M., Richmond N., Valmaseda M., Macarron R.. Process Validation and Screen Reproducibility in High-Throughput Screening. J. Biomol. Screen. 2009 ; 14: 66-76
25. Coma I., Herranz J., Martin J. High Throughput Screening, Methods and Protocol;. 2009 ; 2nd ed., Vol. 565, pp. 69-106. Janzen W. P. Bernasconi P., ed. Totowa, NJ: Humana ; 2009: 69-106.
26. Cottom J., Hofmann G., Siegfried B., Yang J., Zhang H., Yi T., Ho T. F., Quinn C., Wang D.-Y., Johanson K., et al. Assay Development and High-Throughput Screening of Small Molecular c-Abl Kinase Activators. J. Biomol. Screen. 2011 ; 16: 53-64
27. Gamo F.-J., Sanz L. M., Vidal J., de Cozar C., Alvarez E., Lavandera J.-L., Vanderwall D. E., Green D. V. S., Kumar V., Hasan S., et al. Thousands of Chemical Starting Points for Antimalarial Lead Identification. Nature. 2010 ; 465: 305-310
28. Margueron R., Justin N., Ohno K., Sharpe M. L., Son J., Drury W. J., Voigt P., Martin S. R., Taylor W. R., De Marco V., et al. Role of the Polycomb EED in the Propagation of Repressive Histone Marks. Nature. 2009 ; 461: 762-767
29. Quinn A. M., Allali-Hassani A., Vedadi M., Simeonov A.. A Chemiluminescence-Based Method for Identification of Histone Lysine Methyltransferase Inhibitors. Mol. BioSys. 2010 ; 6: 782-788
30. Dirk L. M. A., Flynn E. M., Dietzel K., Couture J.-F., Trievel R. C., Houtz R. L.. Kinetic Manifestation of Processivity during Multiple Methylations Catalyzed by SET Domain Protein Methyltransferases. Biochemistry. 2007 ; 46: 3905-3915
31. Bays N. W., Hill A. D., Kariv I.. A Simplified Scintillation Proximity Assay for Fatty Acid Synthase Activity: Development and Comparison with Other FAS Activity Assays. J. Biomol. Screen. 2009 ; 14: 636-642
32. Hemeon I., Gutierrez J. A., Ho M.-C., Schramm V. L.. Characterizing DMA Methyltransferases with an Ultrasensitive Luciferase-Linked Continuous Assay. Anal. Chem. 2011 ; 83: 4996-5004
33. Young N. L., DiMaggio P. A., Plazas-Mayorca M. D., Baliban R. C., Floudas C. A., Garcia B. A.. High Throughput Characterization of Combinatorial Histone Codes. Mol. Cell. Proteom. 2009 ; 8: 2266-2284
34. Patnaik D., Chin H. G., Estever P.-O., Benner J., Jacobsen S. E., Pradhan S.. Substrate Specificity and Kinetic Mechanism of Mammalian G9a Histone H3 Methyltransferase. J. Biol. Chem. 2004 ; 279: 53248-53258
35. Xiao B., Jing C., Wilson J. R., Walker P. A., Vasisht N., Kelly G., Howell S., Taylor I. A., Blackburn G. M., Gamblin S. J.. Structure and Catalytic Mechanism of the Human Histone Methyltransferase SET7/9. Nature. 2003 ; 421: 652-656
36. Couture J. F., Dirk L. M. A., Brunzelle J. S., Houtz R. L., Trievel R. C.. Structural Origins for the Product Specificity of SET Domain Protein Methyltransferases. Proc. Natl. Acad. Sci. U. S. A. 2008 ; 105: 20659-20664
37. Horowitz S., Yesselman J. D., Al-Hashimi H. M., Trievel R. C.. Direct Evidence for Methylgroup Coordination by CHO Hydrogen Bonds in SET Domain Methyltransferases. J. Biol. Chem. 2011 ; 286: 18658-18663
38. Lakowski T. M., Frankel A.. A Kinetic Study of Human Protein Arginine N-methyltransferse 6 Reveals a Distributive Mechanism. J. Biol. Chem. 2008 ; 283: 10015-10025